BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha
The interaction between interferon treatment and BRAF mutation status among melanoma patients have yet to be evaluated. The present study aims to assess the intermediate dose interferon (IDI) in stage III melanoma patients with respect to BRAF mutation status.
A total of 46 adult lymph node-positive primary skin melanoma patients (23 BRAF-mutant and 23 BRAF-wild) with available information on the mutational status of the oncogene BRAF V600E were included in the analysis. BRAF V600E mutation was detected using the real-time PCR in the formalin-fixed paraffin-embedded samples. All the patients were treated with adjuvant IDI. IFN-alpha-2b was administered 10 MU per day, subcutaneously, three times per week for 1 year.
The distribution of patient numbers between the clinicopathological variables and BRAF mutation status was well balanced. Most of the patients relapsed (83%); however, no significant differences were found between recurrence frequencies and recurrence sites in accordance with BRAF mutation status. BRAF-mutant melanomas were found to be significantly advantageous in disease-free survival (HR 0.464, p = 0.03). More deaths occurred in BRAF-wild-type patients (67%) (p = 0.03), and BRAF mutation was found to be a favorable prognostic factor for overall survival (HR 0.373, p = 0.04).
The presence of BRAF mutation in stage III melanoma patients treated with IDI might contribute a favorable effect on both disease-free survival and overall survival.
KeywordsMelanoma BRAF mutation Interferon Survival
We thank Prof. Ugur Gezer for valuable contribution in the preparation of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
Informed consent was obtained from all individual participants included in the study. The study was reviewed and approved by our local ethical committee.
All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
- 4.Hauschild A. Adjuvant melanoma therapy: European perspective. https://rvmais.com.br/simposiomelanoma/aulas/26/1630-1700-Axel%20Hauschild.pdf. Accessed 2 Mar 2019
- 5.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cutaneous melanoma. Version 1.2019-November 1, 2018Google Scholar
- 7.Bhatia P, Friedlander P, Zakaria EA, Kandil E (2015) Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. Ann Transl Med 3:24Google Scholar
- 14.Wang X, Mao LL, Si L, Chi Z, Cui C, Sheng XN (2015) Efficacy of high-dose adjuvant interferon therapy in high-risk melanoma harboring gene mutations. J Clin Oncol 33(Suppl):abstr 9047Google Scholar